en · de · es · pt
thymosin-alpha-1-notes.peptides6155.com › Guide › Molecular Identity Of Thymosin Alpha-1 — Common Mistakes

Molecular Identity Of Thymosin Alpha-1 — Common Mistakes

By Editorial Desk · published 2025-07-05 · last reviewed 2025-07-22 · Guide

lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-07-22. Anything still debated is marked as such rather than presented as settled.

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Handling, Storage, and Analytical Verification

Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.

Thymosin-alpha-1 at a glance

PropertyValueNotes
ClassSynthetic peptide28 residues; not a small-molecule compound
Molecular massAbout 3,106 DaMonoisotopic mass of the unmodified chain
N-terminal groupAcetylated serinePresent in both native and synthetic forms
Secondary structureDisulfide-constrained loopOne bridge between two cysteine residues
Typical sourceSolid-phase synthesisEarly isolates came from bovine thymus extracts

分子身份与天然来源

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

Related pages on this site

Molecular Background and Immune Action

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Background and Molecular Identity

Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

Research History and Clinical Assessment

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Supporting material

== Possible therapies == Calorie restriction, vitamin E, and increased glutathione appear to reduce or halt the production of lipofuscin. The nootropic drug piracetam appears to significantly reduce accumulation of lipofuscin in the brain tissue of rats. Other possible treatments:

PA 6 or Nylon 6: [NH−(CH2)5−CO]n made from ε-caprolactam. Two numbers or sets of letters indicate a dyadic homopolymer formed from two monomers: one diamine and one dicarboxylic acid. The first number indicates the number of carbons in the diamine. The two numbers should be separated by a comma for clarity, but the comma is often omitted.

== History == It was discovered through the use of high-throughput screening of 25,000 compounds. Toltrazuril and ponazuril (ACD855), two veterinary antiparasitic agents, were identified as possessing Trk-potentiating activity with this screen in 2013. ACD856 was derived via structural optimization of these compounds. In the case of ponazuril, this drug was said to have had too long of an elimination half-life to allow for development for use in humans. ACD856 was first described in the scientific literature by 2021.

== Relationship to docking methods == The field of protein–protein interaction prediction is closely related to the field of protein–protein docking, which attempts to use geometric and steric considerations to fit two proteins of known structure into a bound complex. This is a useful mode of inquiry in cases where both proteins in the pair have known structures and are known (or at least strongly suspected) to interact, but since so many proteins do not have experimentally determined structures, sequence-based interaction prediction methods are especially useful in conjunction with experimental studies of an organism's interactome.

Sources: en.wikipedia.org

Notes from published material

The World's Water Data Page FAO Comprehensive Water Database, AQUASTAT The Water Conflict Chronology: Water Conflict Database Archived 16 January 2013 at the Wayback Machine Water science school (USGS) Portal to The World Bank's strategy, work and associated publications on water resources America Water Resources Association Archived 24 March 2018 at the Wayback Machine Water on the web Water structure and science Archived 28 December 2014 at the Wayback Machine "Why water is one of the weirdest things in the universe", Ideas, BBC, Video, 3:16 minutes, 2019 The chemistry of water Archived 19 June 2020 at the Wayback Machine (NSF special report) The International Association for the Properties of Water and Steam Archived 27 September 2022 at the Wayback Machine H2O: The Molecule That Made Us, a 2020 PBS documentary

Anne S. Ulrich (born December 31, 1966) is a German chemist. She is the director of the Institute of Biological Interfaces (IBG-2) and Chair of Biochemistry at the Karlsruhe Institute of Technology. She studied chemistry at the University of Oxford - continued her doctoral work in the laboratory of Anthony Watts - held subsequent research positions as an EMBO-Fellow with Hartmut Oschkinat at the European Molecular Biology Laboratory in Heidelberg and as a Liebig-Fellow with Felix Wieland at the University of Heidelberg - became Associate Professor at the University of Jena - until she moved her group in 2002 to the Karlsruhe Institute of Technology. Her research focuses on the structural and functional analysis of biomembranes by solid state NMR. The main systems of interest are:

When an 235U atom captures a neutron, it is converted to an excited state of 236U. About 85.5% of the excited 236U nuclei undergo fission, but the remainder decay to the ground state of 236U by emitting gamma radiation. Further neutron capture forms 237U which has a half-life of 7 days and quickly decays to 237Np through beta decay. During beta decay, the excited 237U emits an electron, while the atomic weak interaction converts a neutron to a proton, thus creating 237Np.

=== PPAR-delta agonists === PPARδ (delta) is the main target of a research chemical named GW501516. It has been shown that agonism of PPARδ changes the body's fuel preference from glucose to lipids. In August 2024, seladelpar became the first PPARδ agonist to be approved for clinical use.

Codon reassignment is the biological process via which the way the genetic code of a cell is read is changed as a response to the environment. Typically codons, sets of three mRNA nucleotides, correspond to one specific amino acid. Codon reassignment is the exception to this rule. When a codon is reassigned, it codes for a new amino acid. This change in code can have immense consequences for the cell as protein structures are altered.

Sources: en.wikipedia.org

Frequently asked questions

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Why is the disulfide bridge important?

The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.

How does it differ from other thymic peptides?

It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.

Why is the peptide stored frozen?

Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.

Network